Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Quiet Period To End on March 12th

Maze Therapeutics’ (NASDAQ:MAZE) quiet period will end on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its IPO on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. During Maze Therapeutics’ quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MAZE shares. Guggenheim assumed coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price target for the company. JPMorgan Chase & Co. began coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 target price for the company. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Leerink Partnrs raised Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 25th. Finally, Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 target price for the company. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Price Performance

NASDAQ:MAZE opened at $11.84 on Wednesday. Maze Therapeutics has a 12 month low of $10.08 and a 12 month high of $17.00.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.